StockNews.com Downgrades Relx (NYSE:RELX) to Hold

Relx (NYSE:RELX) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

Separately, Redburn Atlantic initiated coverage on shares of Relx in a research note on Wednesday, January 8th. They set a “buy” rating for the company.

Relx Price Performance

Relx stock opened at $48.55 on Tuesday. The company has a current ratio of 0.52, a quick ratio of 0.47 and a debt-to-equity ratio of 1.46. The stock has a market cap of $90.24 billion, a P/E ratio of 26.10, a PEG ratio of 2.73 and a beta of 0.90. The company has a 50-day moving average price of $48.54 and a 200 day moving average price of $47.52. Relx has a 12-month low of $40.25 and a 12-month high of $51.99.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. CENTRAL TRUST Co raised its holdings in Relx by 1,290.2% during the fourth quarter. CENTRAL TRUST Co now owns 570 shares of the technology company’s stock worth $26,000 after purchasing an additional 529 shares in the last quarter. Versant Capital Management Inc acquired a new stake in shares of Relx in the 4th quarter worth $31,000. Transce3nd LLC acquired a new stake in shares of Relx in the 4th quarter worth $40,000. Sierra Ocean LLC purchased a new stake in Relx during the fourth quarter worth about $43,000. Finally, Brown Brothers Harriman & Co. boosted its holdings in Relx by 218.5% during the fourth quarter. Brown Brothers Harriman & Co. now owns 965 shares of the technology company’s stock worth $44,000 after buying an additional 662 shares in the last quarter. Hedge funds and other institutional investors own 15.02% of the company’s stock.

Relx Company Profile

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.